Kristin Higgins, MD

Articles by Kristin Higgins, MD

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Second- and Third-Line Treatment for ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Expert Approaches to Treating Extensive Stage SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Roy S. Herbst, MD, PhD, Yale Cancer Center,Stephen Liu, MD, MedStar Georgetown University Hospital,Kristin Higgins, MD

July 6th 2020

Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC

ByKristin Higgins, MD

April 24th 2014

Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy.

Latest Updated Articles

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC
Published: July 6th 2020 | Updated:
Review of Treatment for Limited-Stage Small-Cell Lung Cancer
Published: July 6th 2020 | Updated:
Role of PCI Versus Brain MRI Surveillance in ES-SCLC
Published: July 6th 2020 | Updated:
Expert Approaches to Treating Extensive Stage SCLC
Published: July 6th 2020 | Updated:
IMpower133 and CASPIAN Trials for Extensive Stage SCLC
Published: July 6th 2020 | Updated:
Second- and Third-Line Treatment for ES-SCLC
Published: July 6th 2020 | Updated:

Kristin Higgins, MD

Articles by Kristin Higgins, MD

Review of Treatment for Limited-Stage Small-Cell Lung Cancer

Second- and Third-Line Treatment for ES-SCLC

Role of PCI Versus Brain MRI Surveillance in ES-SCLC

Expert Approaches to Treating Extensive Stage SCLC

KEYNOTE-604 and ECOG-ACRIN 5161 Trials for ES-SCLC

IMpower133 and CASPIAN Trials for Extensive Stage SCLC

Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma